Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis-Reference-Cited by-同舟云学术

Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis

Author:

Ohlssen David¹,Price Karen L.²,Amy Xia H.³,Hong Hwanhee⁴,Kerman Jouni⁵,Fu Haoda²,Quartey George⁶,Heilmann Cory R.²,Ma Haijun³,Carlin Bradley P.⁴

Affiliation:

1. Novartis Pharmaceuticals Corporation; East Hanover NJ 07936 USA

2. Eli Lilly and Company; Indianapolis IN 46285 USA

3. Amgen, Inc; Thousand Oaks CA USA

4. Division of Biostatistics; University of Minnesota; Minneapolis MN USA

5. Novartis Pharma AG; Basel Switzerland

6. Genentech, Inc; South San Francisco CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

Reference78 articles.

1. Experiences with meta-analysis in NDA submissions;Huque;Proceedings of the Biopharmaceutical Section American Statistical Association,1988

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Network meta-analysis for clinicians;Journal of Modern Oncology;2021-11-19

4. Classifying information-sharing methods;BMC Medical Research Methodology;2021-05-22